Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03299751
Other study ID # 69HCL17_0492
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 22, 2017
Est. completion date November 20, 2020

Study information

Verified date September 2022
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Late-onset neonatal sepsis (LOS), occurring in newborn of at least 7 days of life, is frequently observed in Neonatal Intensive Care Units (NICUs) and potentially severe (mortality, neurologic and respiratory impairments). Despite its high prevalence, a reliable diagnostic remains difficult. Currently, nonspecific clinical signs that might be linked to other neonatal conditions, such as prematurity and birth defects are used to determine the diagnosis of LOS. Laboratory results of biological markers, such as C-Reactive Protein (CRP) and Procalcitonin (PCT) are often delayed in comparison with LOS onset. Blood culture results are too late and lack sensitivity. Excessive antibiotic use is observed in a large proportion of NICU hospitalized newborns. This results in an increased antibiotic resistance, microbiota modification, neonatal complications (pulmonary, ophthalmologic and neurologic) and mortality. The primary objective is to identify, on a cohort of 250 patients, the optimal biomarker combination with good diagnostic performance (i.e. with maximal Area Under the ROC Curve) to early exclude a LOS diagnostic in newborns of at least 7 days of life with suggestive signs. This identification will be carried out, as a secondary objective, with a sub-group of pre-term neonates whose birth weight is less than 1500 grams. The diagnostic value of the clinical signs that are suggestive of LOS will also be determined (sensitivity, specificity, negative and positive predictive values). Once identified, the biomarker combination is expected to reduce unjustified antibiotic use.


Recruitment information / eligibility

Status Completed
Enrollment 233
Est. completion date November 20, 2020
Est. primary completion date November 20, 2020
Accepts healthy volunteers No
Gender All
Age group 7 Days and older
Eligibility Inclusion Criteria: - patients hospitalized in NICU; - patients with suggestive signs of LOS including at least one of the following: o Fever > 38°C; tachycardia > 160bpm160 bpm; capillary refill time > 3 seconds; grey and/or pale skin complexion; apnea/ bradycardia syndrome,; bloating; rectal bleeding; hypotonia; lethargy; seizures without other obvious cause; increased ventilatory support and/or increased FiO2; cutaneous rash; inflammation at the needle-puncture site of the central venous catheter; - patients with a standard of care blood sampling, including at least a blood culture; - consent form signed by at least one parent/ legal representative. Exclusion Criteria: - patients treated with antibiotics for a bacteriologically confirmed infection at the moment of/ or 48 hours before blood sampling - patients who underwent surgery during the 7 days prior to inclusion - patients vaccinated during the 7 days prior to inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Diagnostic performances of biomarkers combination
A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care. The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.

Locations

Country Name City State
France Hospices Civils de Lyon Bron
France CHU de Nantes Nantes

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary LOS diagnosis in NICU newborns of at least 7 days of life with suggestive clinical signs, confirmed by adjudication committee The primary outcome measure will be determined by an independent adjudication committee that will classify the patients into the following categories: infected, not infected or unclassified patients. This committee will be blinded to the biomarkers that will be used to identify a combination with the best negative predictive value. It will be composed of two neonatologists and a pediatrician specialized in the child infectious diseases.
The diagnostic performance of the biomarkers combination will be based on the adjudication committee
hour 48
Secondary LOS diagnosis in NICU preterm neonates, whose weight at birth is less than 1500 grams, of at least 7 days of life, with suggestive clinical signs, confirmed by adjudication committee. The primary outcome measure will be determined by an independent adjudication committee that will classify the patients into the following categories: infected, not infected or unclassified patients. This committee will be blinded to the biomarkers that will be used to identify a combination with the best negative predictive value. It will be composed of two neonatologists and a pediatrician specialized in the child infectious diseases.
The diagnostic performance of the biomarkers combination will be based on the adjudication committee classification (gold standard).
Hour 48
See also
  Status Clinical Trial Phase
Recruiting NCT05530330 - Markers of Platelet Activation foR Identification of Late Onset Sepsis in Preterm Infants
Not yet recruiting NCT06199102 - The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. N/A
Recruiting NCT04717037 - Olive Oil Massage Effect for Reduction of Preterm Sepsis (OMEPS) Phase 2/Phase 3
Not yet recruiting NCT06118801 - The Effect of Probiotics Added to the Mother's Diet on Preterm Babies N/A
Recruiting NCT04842786 - Topical Coconut Oil Application and Incidence of Sepsis in Neonates N/A
Completed NCT03822104 - Bovine Colostrum as a Human Milk Fortifier for Preterm Infants N/A
Completed NCT04424667 - Clinical Impact of Donor Milk Pasteurized by HTST Treatment in Preterm Infants N/A
Recruiting NCT05981079 - Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis. Phase 4
Recruiting NCT05991648 - Effect of Kangaroo Care on Heart Rate Variability in Late-onset Neonatal Sepsis N/A
Completed NCT03085277 - Bovine Colostrum for Preterm Newborns N/A
Recruiting NCT05347238 - Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis
Completed NCT04792918 - Characterization of Intestinal Microbiota Stability in Preterm Born Neonates
Recruiting NCT03997266 - NICU Antibiotics and Outcomes Trial Phase 4
Completed NCT03633500 - Effectiveness of Oral Immunotherapy Among Preterm Babies N/A